TME Modifier (eTreg depletor)
NT5010 is an eTreg (effector regulatory T cell) depletive technology aimed at improving anticancer responses by selectively eliminating Treg cells that contribute to immune dysfunction within tumors.
NeoImmuneTech is developing Treg-depleting antibodies that target two specific markers found in tumors. The goal is to reduce Treg cell populations within tumors while minimizing any impact on Treg cells present in the bloodstream.
Target Indication: Solid Tumors
Conceptual Structure of NT5010
NT5010 targets two eTreg markers to elevate selectivity for eTreg.